The neonatal form of GA I1 is a serious metabolic disorder with symptoms starting within the first days of life (3, 7, 8, 11, 14) . The infants with this disorder become lethargic and hypotonic, they develop severe hypoglycemia and acidosis. Death usually occurs a few days after onset of symptoms. Biochemically, the disease is characterized by the urinary excretion of a number of organic acids that all seem to be derived from substrates to a group of FAD containing acyl-CoA dehydrogenases (8, 1 1). Some of the patients have also been noted to have high plasma sarcosine and to excrete elevated amounts of sarcosine in the urine (7, 8) .
This abnormal metabolic pattern is explained by deficiency of the enzyme systems of the fatty acid acyl-CoA dehydrogenation, the acyl-CoA dehydrogenation involved in the degradation of the three branched chain amino acids, the glutaryl-CoA dehydrogenation and the sarcosine dehydrogenation (8) .
A normal synthesis of FAD by kidney homogenate from one patient indicated the presence of normal amounts of this coenzyme for all the involved dehydrogenases (7) .
Fibroblasts from patients with GA I1 have shown diminished ability to oxidize 14C-labeled substrates for the flavoprotein acylCoA dehydrogenases (1 1, 12) .
A defect in ETF common for all the defective dehydrogenases has been suggested by several investigators including ourselves (7, 8) . Recently, the ETF has been measured in fibroblasts from the first reported patient with glutaric aciduria type 11 and found to be normal or increased (12) . The present work describes the investigations performed on cultured skin fibroblasts from our patient with GA I1 to further characterize the defect. Normal uptake of [2-'4C] riboflavin and normal synthesis of FMN and FAD was found. The oxidation of (C6-C16) 1-14C-fatty acids and [6-14C] lysine to I4CO2 was significantly decreased in intact fibro-. blasts from the patient. The glutaryl-CoA and medium chain (C6-CIO) acyl-CoA dehydrogenases in fibroblast homogenate were normal using artificial electron acceptors. However, glutaryl-CoA dehydrogenase activity was very much decreased with intact ETC. These results are consistent with the proposed defect of ETF or ETF-DH.
MATERIALS AND METHODS
The chemicals used were obtained from the following sources.
[1,5-'4C]glutaric acid and ~~-[ 6 -'~C ] l y s i n e from CIS (France, Belgium, and Italy); l-14C-labeled even-numbered fatty acids from New England Nuclear; [2-14C] riboflavin from Amersham, England; riboflavin, FMN, FAD, and CoA from Boehringer, Germany; DCPIP, MB, and trichloroacetic acid from Merck, Germany; methylbenzethonium hydroxide (Hyamin) from Sigma; L-lysine HC1 from Calbiochem, Switzerland; fetal Calf serum from Gibco, Scotland; medium 199, DPBS, and Hank:; balanced salts from Flow Laboratories, Scotland; and Insta-Fluor and Insta-Gel from Packard Instrument Company.
Assays ,for glutaryl-CoA dehydrogenase. The first method to detel-mine GDH activity used MB as EA as earlier described (1, 2; Fig. 1 ). The second method measured GDH activity without exogenous EA and was dependent on the intact endogenous ETS. Different homogenizing procedures were investigated with this method. The procedure that gave the highest activity in normal fibroblasts was chosen as the method for investigating the activity in fibroblasts from GA I1 patients. The first method determined GDH activity alone whereas the second method also measured the endogenous ETS (see Fig. 2 ). The second method was thus able to detect defects in GDH as well as in ETS. All assays were performed in duplicate. The values shown in Tables  5, 6 , and 7 were the results of three or more separate determinations. Estimation of the oxidation rate for [6-I4C] lysine. Oxidation of [6-'4C] lysine was performed by a method modified from Dancis et ul. (4) . Fibroblasts were grown to confluence in 25-cm' flasks. The cells were washed three times with 5 ml DPBS with the cells still attached to the bottom. 0.5 ml DPBS containing 0.33 mmol/liter [6-14C] lysine (specific activity, 2.5. mCi/ mol) was added and the flasks were incubated at 37°C for 4 h. Scintillation flasks containing a piece of pleated filter paper moistened with 100 ~1 Hyamin were attached to the culture flasks by means of a piece of rubber tubing during incubation. The incubation was stopped by injection of 100 of 30% trichloroacetic acid into the culture flasks through the rubber tubing. The released 14C02 was collected, while shaking the flasks gently at 37°C for a further 60 min. 10 ml Insta-Fluor was added to each scintillation flask and the amount of I4CO2 was counted in a Betaszint scintillation counter. The cell monolayer was dissolved in a strong base and aliquots were used for protein determination using the Lowry method (10).
Oxidation of l-'4CTfutty acid^ (C(,-CI6). The determination of the rate of fatty acid oxidation was performed as earlier described (9) . was performed by selected ion monitoring gas chromatography/ mass spectrometry of the 3-OH-acids formed from the reaction products after enzymatic hydration of the unsaturated acyl-CoA derivatives by purified crotonase and hydrolysis of the thioesters. The method has been described in detail elsewhere (9) .
FAD and FMN synthesis infihrohla.rts: Method I. Fibroblasts were grown to confluence in 75-cm2 Falcon Flasks in medium 199 containing 15% fetal calf serum. For measuring riboflavin uptake and conversion, the growth medium was replaced by medium 199 without fetal calf serum but containing 20 Pmol/ liter [2-'4C]riboflavin (specific activity, 60 mCi/mmol). After incubation for 24 h at 37"C, the incubation was stopped and cells washed three times with 10 ml DPBS. The cells were then harvested with trypsin-EDTA and further washed twice with DPBS. 3 ml of a solution containing 0.033 mg/ml riboflavin, FMN, and FAD were added. The cells were homogenized in a Potter-Elvehjem homogenizer. subjected to three cycles of freezing and thawing, and finally sonified 3 x 10 sec on a MSE 150-W Sonifier. An aliquot was used for protein determination. 6 ml methanol was added to the rest of the homogenate and proteins were allowed to precipitate at 4°C for 18 h in the dark. The precipitate was pelleted by centrifugation for 30 min at 3000 x g. 5 ml of the supernatant was evaporated to dryness in a stream of nitrogen. The residue was redissolved in 2 ml distilled water and applied to a DEAE-Sephadex A-25 column. Riboflavin and its derivatives were then eluted by 1% ammonium sulfate as described by Fazekas and Sandor (6) .
Fractions containing the individual flavins were pooled and a fraction was mixed with Insta-gel and counted in a liquid scintillation counter. The intracellular concentrations of labeled riboflavin, FMN, and FAD were expressed as cpm/mg protein.
Method II. Fibroblasts were grown to confluence in 75-cm2 Falcon flasks in medium 199 containing 15% FCS. The medium was then replaced by 0.040 Irmol/liter [2-4C]riboflavin (specific activity, 60 mCi/mmol) dissolved in Hanks' balanced salt solution. The cells were incubated for 4 h at 37°C. The measurement of the intracellular concentration of labeled riboflavin, FMN, and FAD was then performed as for method I.
RESULTS
The ability of the mutant fibroblasts to take up [2-'4C]riboflavin and convert it to labeled FMN and FAD was similar to that of fibroblasts from normal individuals (Table 1) . This was the case both at a saturated [2-14C] riboflavin concentration, where an increase in [2-'4C]riboflavin did not result in a further increase in FAD synthesis and at a low [2-14C]riboflavin concentration with no saturation of FAD synthesis. Table 2 shows the oxidation rates for 1-I4C-labeled evennumbered fatty acids (C(,-CI6) by intact fibroblasts from normal individuals and the patient. A significant decrease in the ability to oxidize 1-14C-fatty acids is seen for the mutant fibroblasts.
The oxidation rates of ~~-[ 6 -~~C ] l y s i n e by different mutant cell lines is compared to cell lines from normal individuals in Table 3 . The lowest oxidation rate is seen in two patients with hyperlysinemia. The oxidation rate in the patient with GA I1 is about half the normal rate and similar to the rate in patients with GA I.
Medium chain acyl-CoA dehydrogenase activity estimated by direct dehydrogenation of (CO-CIO) acyl-CoA by fibroblast homogenate is shown in Table 4 . Normal activity was found in the homogenates of G A I1 fibroblasts. Glutamate dehydrogenase was determined as a reference mitochondria1 enzyme. The normal dehydrogenation of (C6-CIO) acyl-COAS by fibroblast lysate from GA I1 patients is in contrast to the very decreased oxidation by intact cells of (Ch-Clh) fatty acids as seen in Table 2 and indicates that the dehydrogenases are functioning normally.
In order to investigate the influence of the homogenizing procedure, G D H activities have been measured in normal fibroblasts both with MB and without any exogenous EA, but with intact endogenous ETS after five different homogenizing procedures as shown in Table 5 . The highest activity with MB as EA was obtained with procedure I. This was comparable to the previously reported procedure (2). The measured activity with MB as EA decreased when part of the procedure was omitted, and less than 10% of normal activity when only one stroke of a Potter-Elvehjem homogenizer was used. The G D H activity with no exogenous EA but with intact endogenous ETS on the contrary increased with less vigorous homogenizing procedure. Maximum activity was obtained with one freeze-thaw cycle after Potter-Elvehjem homogenizing. Without the freeze-thaw cycle, the activity decreased as did the activity with MB as EA. Centrifugation of the fibroblast homogenate for 1 hr at 50,000 X g completely abolished the glutaryl-CoA dehydrogenase activity without exogenous EA as did the addition of 0.1% Triton X-100, while the MB-dependent activity was unchanged. In agreement with the results from Table 5 , homogenizing procedure IV was used for the determination o f G D H activity with endogenous EA (i.c. intact ETC).
In Table 6 Table 7 both with endogenous EA and with MB as EA. The activities in normal individuals with MB as EA are lower than previously reported (2) . This is caused by the suboptimal homogenizing procedure for this method.
GA I heterozygotes showed the same ratio as normal homozygotes between the activity measured with endogenous EA and the activity with MB as EA (see last column in Table 7 ). GA I homozygotes have no activity with either endogenous ETS or MB as EA whereas GA I1 homozygotes have normal activity measured with MB as EA but very low activity with endogenous EA (i.e. with intact ETC). In contrast to GA I heterozygotes with half-normal activity with both assay methods, GA I1 heterozygotes cannot be distinguished from normal homozygotes by these two methods.
DISCUSSION
All cases of neontal GA I1 described have been characterized by the urinary excretion of a great number of organic acids that all seem to be derived from substrates to a group of FADcontaining acyl-CoA dehydrogenases (8) . Besides FAD, these dehydrogenases have in common a transfer of electrons through ETF and ETF-DH to CoQlo in the ETC (see Fig. 2 ). The normal activities of the fatty acyl-CoA dehydrogenases and of G D H measured on fibroblast homogenate with artificial electron acceptors strongly indicate that the dehydrogenases themselves are functioning normally in GA 11.
A defect in a common factor for all of the involved dehydrogenases has been considered. One such factor is FAD, the common prosthetic group for all the apparently involved enzymes. A decreased synthesis of FAD as already suggested by Przyrembel et ul. ( I I) could be the cause of the defective function of the dehydrogenases in vivo. Goodman et al. (7) investigated the ability of an autopsy kidney specimen from one of his patients with GA I1 to synthesize FMN and FAD from [2-14C]riboflavin and found no difference between autopsy kidney from the patient and three controls. As has been reported that whole liver homogenate only has slight net synthesis of FMN and FAD due to degradation by factors contained in the mitochondria (5), we decided to reinvestigate the FMN and FAD production from [2-'4C]riboflavin in our patient using whole living fibroblasts as the tissue for investigation.
Two different methods were used: one using 24-h incubation in normal medium and a high [2-'4C]riboflavin concentration and one using 4-h incubation in a salt solution containing glucose but without unlabeled riboflavin and a rather low [2-'4C]riboflavin concentration not saturating the FMN-and FAD-synthesizing system. The latter system should be able to detect a defective uptake of riboflavin by the mutant cells. Both methods showed normal FAD synthesis by the mutant cells, thus confirming the results by Goodman et al. (7) that FAD synthesis is normal in patients with GA 11.
ETF and ETF-DH are essential factors for the FAD-containing icate as the ETF source and assumed the reduction in DCPIP to be a measure of the ETF activity. However, the fibroblast mitochondrial sonicate contains thiolases which hydrolyze octanoylCoA and liberate thiol groups that are able to reduce DCPIP ( 12) . As ETF and ETF-DH activity seems difficult to measure in fibroblasts, we have tried to obtain an indirect measure of their combined activity by measuring GDH with intact ETS and without exogenous EA. GDH activity is then dependent on both a normal GDH, ETF, ETF-DH, and an intact ETC. GA I1 homozygotes have very low activity using this method whereas they have normal activity with MB as EA. These results strongly indicate a normal GDH apoenzyme but that one of the components in the electron transport chain from GDH to molecular oxygen is defective. As the oxidation of NADH and succinate seems to be normal in GA 11, the ETC from CoQlo to O2 is very likelv also intact ( 13) . The ~ossible defect in GA I1 is then limited to ETF or ETF-DH:
Neonatal GA I1 has been suggested to be inherited as an Xlinked disease (3). The support for this has been that most of the patients found so far have been male infants. However, the case described by us who had the severe neonatal form of the disease was a female. This leads to different possibilities. The severe neonatal form can be a heterogenous group with more than one biochemical defect, one being X-linked and one autosomal recessively inherited. A way to distinguish between these possibilities would be to show half-normal activity in the GA I1 parents. As the exact defect in GA I1 is not known at present, this must be done indirectly. The oxidation of fatty acids in intact GA I1 fibroblasts is very much decreased (see Table 2 ). If intermediate oxidation rates of fatty acids could be shown in parents of GA I1 patients, this would strongly support a recessive inheritance. Our method that measures GDH with intact ETC as EA to diagnose GA I1 cannot distinguish the parents from normal individuals although the method measures half-normal activities in GA I parents (see Table 7 ). An explanation for this discrepancy could be that GDH is the limiting factor in this assay as indicated by the intermediate values in the obligate GA I heterozygotes. Halfnormal concentration of ETF or ETF-DH would then still be enough for full GDH activity. Another possibility is that the synthesis of the missing enzyme in GA I1 (i.e. ETF or ETF-DH) is regulated so the one gene that is functioning in GA I1 heterozygotes keeps working until a normal enzyme level is reached. This cannot occur in GA I1 homozygotes where both genes are defective.
Although the normal GDH activity measured with intact ETC as EA is a disadvantage in the diagnosis of GA I1 heterozygotes, it makes prenatal diagnosis of GA 11 homozygotes easier because of the high difference in enzyme activities between GA I1 heterozygotes and homozygotes.
